|
Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)
|
12 Months Ended |
|
Dec. 31, 2013
|
Dec. 31, 2012
|
| Revenues: |
|
|
| License and milestone revenue |
$ 0 |
$ 7,523,438 |
| Research revenue |
0 |
186,233 |
| Total revenues |
0 |
7,709,671 |
| Operating expenses: |
|
|
| Research and development |
5,122,864 |
2,281,196 |
| General and administrative |
3,635,690 |
1,551,199 |
| Reverse merger costs |
1,011,630 |
0 |
| Settlement for termination of certain rights in stock purchase agreement |
913,446 |
0 |
| Total operating expenses |
10,683,630 |
3,832,395 |
| Operating income (loss) |
(10,683,630) |
3,877,276 |
| Other income, net |
38,476 |
10,313 |
| Income (loss) before income tax expense |
(10,645,154) |
3,887,589 |
| Income tax benefit (expense) |
55,048 |
(684) |
| Net income (loss) |
(10,590,106) |
3,886,905 |
| Basic earnings (loss) per share attributable to common stock (in dollars per share) |
$ (1.44) |
$ 0.85 |
| Weighted average common shares outstanding, basic (in shares) |
7,363,076 |
4,455,790 |
| Diluted earnings (loss) per share attributable to common stock (in dollars per share) |
$ (1.44) |
$ 0.85 |
| Weighted average common shares outstanding, diluted (in shares) |
7,363,076 |
4,455,790 |
| Comprehensive income (loss) |
$ (10,590,106) |
$ 3,886,905 |